Plexus Ventures Assists Valeas S.p.A. to acquire from Pharmactive Biotech Products, SL, Spain licensing and distribution rights for its premium Affron®-based product for commercialization in Italy

May 31, 2022

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Valeas S.p.A.

Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: 
“This agreement allows Valeas to extend its CNS portfolio adding a premium product based on natural, patented ingredient Afforn®. The product will satisfy the growing demand among the consumers looking for mood improvement medication that offers science-based and, at the same time, natural solution to their problem.

About Valeas
Valeas is an Italian pharmaceutical company that focuses on therapeutic areas such as asthma, chronic obstructive bronchitis, upper and lower respiratory tract infections, anxiety, insomnia, and more. The company was founded in 1934 and is based in Milan, Italy. 

About Pharmactive
Pharmactive is a privately-owned Spanish company that develops, and manufactures differentiated natural ingredients supported by scientific evidence. Pharmactive makes these innovative ingredients available to other companies in the Nutraceutical and Pharmaceutical Industries for marketing and distribution.

About Plexus Ventures

Plexus Ventures, founded over 30 years ago, is a leading corporate and business development consultancy for the healthcare industry. Plexus assists clients of all sizes and capabilities to achieve their strategic business development objectives, advising on M&A, asset divestments, licensing and partnership arrangements. Plexus’ industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.